Turkey antirheumatic drugs market was valued at US$1,493.931 million in 2019. The major factor driving the antirheumatic drugs market growth in Turkey includes the rising risk of the reintroduction of localized outbreaks of malaria throughout the country. However, there has been a dramatic decrease in the number of malaria cases and their active foci. Furthermore, the high prevalence of non-communicable disease in the country such as heart diseases, cancer, diabetes, osteoarthritis, and osteoporosis among others is also considered to be one of the key factors bolstering the antirheumatic drugs market growth in the country during the next five years. According to the data from the World Health Organization, non-communicable diseases account for more than 80% of the deaths in the country. Furthermore, the government initiatives to meet the response of the growing burden of non-communicable diseases in the country are also projected to significantly drive the market growth as numerous plans implemented by the country’s Ministry of Health aimed to improve the healthcare sector and its services. For instance, the NCD action plan for 2017-2025. Additionally, the growing geriatric population in the country also supports the market for antirheumatic drugs in Turkey during the next five years. For example, the population aged 65 and above (% of the total population) reached 8.483% by 2018 from 6.993% in the year 2008.
Turkey antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Turkey antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).